2021-11-24
ViewReleaseInStandardHtml

NeoDynamics appoints Aaron Wong as CFO

The medtech company NeoDynamics AB has appointed Aaron Wong as CFO. Aaron Wong most recently comes from a similar position at the medtech company ADDvise Group AB listed on Nasdaq First North. He will assume the new position on February 1, 2022.

Aaron Wong has extensive experience from the industry, financial markets and transactions, which fits in well with the development phase that NeoDynamics is entering. He has previously worked in financial roles at Johnson & Johnson and Informa Group, among others. Aaron Wong holds a BA in Accounting & Finance from De Montford University in Leicester, UK.

”Aaron Wong will be a welcome addition to the team as we now prepare to scale up the business and develop new partnerships,” says CEO Anna Eriksrud.

Aaron Wong will also become a member of the management team.

For further information, please contact:

Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail anna.eriksrud@neodynamics.com

 

 

About NeoDynamics

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in breast and axilla in over 500 patients.

 

About NeoNavia

NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. It consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumour whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.